Issues

Management of renal hyperparathyroidism

Journal: Osteologie
ISSN: 1019-1291
Topic:

Kalzium-Phosphat-Stoffwechsel und Knochen

Issue: Issues of 2017 (Vol. 26): HeIssue 3 2017 (131-191)
Pages: 135-138

  1. Ketteler M, Elder GJ, Evenepoel P et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2015; 87: 502-528. DOI:10.1038/ki.2014.425
  2. Wetmore JB, Santos PW, Mahnken JD et al. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab 2011; 96: E57-E64. DOI:10.1210/jc.2010-1277
  3. Jehle PM. Update Knochenstoffwechsel bei Niereninsuffizienz. „High“ and „low-turnover“ Osteodystrophie. Der Nephrologe 2017; 12: 162-167. DOI:10.1007/s11560-017-0142-1
  4. Jehle PM, Ostertag A, Schulten K et al. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 2000; 57: 423-436. DOI:10.1046/j.1523-1755.2000.00862.x
  5. Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012; 22: 61-86. DOI:10.1615/CritRevEukarGeneExpr.v22.i1.50
  6. Fernández-Martín JL, Martínez-Camblor P, Dionisi MP et al. COSMOS group. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant 2015; 30: 1542-1551. DOI:10.1093/ndt/gfv099
  7. Ghazali A, Fardellone P, Pruna A et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser‘s zones independent of calcitriol? Kidney Int 1999; 55: 2169-2177. DOI:10.1046/j.1523-1755.1999.00480.x
  8. Coen G, Mantella D, Manni M et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005; 68: 1840-1848. DOI:10.1111/j.1523-1755.2005.00603.x
  9. Jehle AM, Jehle PM. Metabolische Azidose: Auswirkungen auf den Knochenstoffwechsel. Nieren- und Hochdruckkrankheiten 2015; 44: S403-S406. DOI:10.5414/NHX01735
  10. Fiedler R, Deuber HJ, Langer T et al. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients. Nephron Clin Pract 2004; 96: c3-c9. DOI:10.1159/000075565
  11. D’Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol TM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63: S73-S78. DOI:10.1046/j.1523-1755.63.s85.18.x
  12. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. DOI:10.1038/sj.ki.5001514
  13. Brandenburg VM, Floege J. Adynamic bone disease - bone and beyond. Nephrol Dial Transplant Plus 2008; 3: 135-147.
  14. Stracke S, Jehle PM, Sturm D et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999; 33: 304-311. DOI:10.1016/S0272-6386(99)70305-7
  15. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951. DOI:10.1097/01.ASN.0000129337.50739.48
  16. Floege J et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955. DOI:10.1093/ndt/gfq219

You may also be interested in...

1.
P. M. Jehle

Osteologie 2008 17 3: 125-134

2.
Clemens Grupp, Florian Weber

arthritis + rheuma 2006 26 1: 22-26

3.
S. Stracke (1), F. Keller (2), D. Henne-Bruns (3), G. Steinbach (4), P. Würl (3)

Osteologie 2009 18 2: 125-127